Metropolis Healthcare Q2 FY27 Profit Soars 43% To ₹75.5 Crore As Diagnostic Demand Gains Momentum, EBITDA Jumps 23.9% To ₹134.9 Crore While Tier III Cities Record 20% Revenue Growth

Mumbai-based Metropolis Healthcare reported a significant surge in profit for the second quarter of FY27, with net profit jumping by 42.7% to ₹75.5 crore, up from ₹52.9 crore in the same period last year. The company's diagnostic services saw double-digit revenue growth driven by higher patient volumes, increased testing activity, and expansion in both consumer and institutional businesses.

The company's quarterly revenue from operations grew by 15.8% to ₹496.8 crore, compared to ₹429.2 crore in Q2 FY26. Earnings before interest, tax, depreciation, and amortisation (EBITDA) rose by 23.9% to ₹134.9 crore, indicating improved operating profitability with a margin expanding by 180 basis points to 27.2%. Patient volumes increased by 10% year-on-year to 4.1 million, while test volumes rose by 11% to 8.7 million, mirroring the revenue expansion.

The business-to-consumer segment generated ₹289 crore, posting a 17% year-on-year growth, while business-to-business revenue increased by 15% to ₹208 crore. Notably, smaller cities, particularly Tier III cities, emerged as Metropolis Healthcare's fastest-growing markets, with revenue from these locations up by approximately 20%, outpacing overall revenue growth.

The company's board of directors declared an interim dividend of ₹1 per equity share. The board's quarterly performance was underpinned by higher testing volumes, stronger revenue, and improved operating margins, with continued growth in smaller cities and sustained demand across B2C and B2B segments seen as crucial indicators for future performance.